Credit Suisse Group lowered shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) to a hold rating in a research note published on Friday. They currently have $485.00 price target on the biopharmaceutical company’s stock.
REGN has been the topic of several other reports. Oppenheimer Holdings, Inc. started coverage on Regeneron Pharmaceuticals in a research report on Thursday, March 16th. They set a hold rating on the stock. Vetr downgraded Regeneron Pharmaceuticals from a sell rating to a strong sell rating and set a $368.84 target price on the stock. in a research report on Monday, May 15th. Leerink Swann set a $448.00 target price on Regeneron Pharmaceuticals and gave the company a buy rating in a research report on Tuesday, March 28th. BTIG Research reiterated a buy rating and set a $460.00 target price on shares of Regeneron Pharmaceuticals in a research report on Wednesday, March 29th. Finally, Robert W. Baird reiterated a neutral rating and set a $369.00 target price on shares of Regeneron Pharmaceuticals in a research report on Tuesday, March 28th. One analyst has rated the stock with a sell rating, sixteen have assigned a hold rating and twelve have issued a buy rating to the stock. The stock presently has an average rating of Hold and a consensus price target of $457.83.
Regeneron Pharmaceuticals (NASDAQ:REGN) traded up 0.08% during mid-day trading on Friday, hitting $498.51. The company had a trading volume of 212,034 shares. Regeneron Pharmaceuticals has a 52 week low of $325.35 and a 52 week high of $543.55. The firm’s 50 day moving average is $474.83 and its 200 day moving average is $400.97. The company has a market capitalization of $52.63 billion, a price-to-earnings ratio of 60.34 and a beta of 1.67.
Regeneron Pharmaceuticals (NASDAQ:REGN) last released its earnings results on Thursday, May 4th. The biopharmaceutical company reported $2.92 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $2.50 by $0.42. The company had revenue of $1.32 billion for the quarter, compared to the consensus estimate of $1.30 billion. Regeneron Pharmaceuticals had a return on equity of 22.99% and a net margin of 19.34%. Regeneron Pharmaceuticals’s quarterly revenue was up 9.8% compared to the same quarter last year. During the same period in the previous year, the business earned $2.57 earnings per share. On average, equities research analysts predict that Regeneron Pharmaceuticals will post $12.72 EPS for the current year.
TRADEMARK VIOLATION NOTICE: “Credit Suisse Group Downgrades Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) to Hold” was originally reported by Sports Perspectives and is the property of of Sports Perspectives. If you are reading this piece of content on another site, it was stolen and republished in violation of US & international trademark and copyright law. The original version of this piece of content can be viewed at https://sportsperspectives.com/2017/07/18/credit-suisse-group-downgrades-regeneron-pharmaceuticals-inc-nasdaqregn-to-hold.html.
In other news, Chairman P Roy Vagelos sold 9,295 shares of the company’s stock in a transaction that occurred on Thursday, May 25th. The stock was sold at an average price of $458.14, for a total transaction of $4,258,411.30. Following the transaction, the chairman now owns 414,156 shares of the company’s stock, valued at $189,741,429.84. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Also, Director Joseph L. Goldstein sold 1,000 shares of the company’s stock in a transaction that occurred on Friday, June 9th. The shares were sold at an average price of $482.55, for a total value of $482,550.00. Following the transaction, the director now directly owns 14,000 shares in the company, valued at approximately $6,755,700. The disclosure for this sale can be found here. Insiders have sold 59,396 shares of company stock worth $28,484,734 over the last three months. 10.40% of the stock is currently owned by insiders.
Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Korea Investment CORP boosted its position in Regeneron Pharmaceuticals by 223.9% in the first quarter. Korea Investment CORP now owns 298 shares of the biopharmaceutical company’s stock worth $115,000 after buying an additional 206 shares in the last quarter. FNY Managed Accounts LLC acquired a new position in Regeneron Pharmaceuticals during the first quarter worth approximately $140,000. Alpha Windward LLC boosted its position in Regeneron Pharmaceuticals by 4.4% in the first quarter. Alpha Windward LLC now owns 383 shares of the biopharmaceutical company’s stock worth $148,000 after buying an additional 16 shares in the last quarter. Welch & Forbes LLC acquired a new position in Regeneron Pharmaceuticals during the first quarter worth approximately $211,000. Finally, Comerica Securities Inc. acquired a new position in Regeneron Pharmaceuticals during the first quarter worth approximately $213,000. 66.87% of the stock is currently owned by hedge funds and other institutional investors.
Regeneron Pharmaceuticals Company Profile
Regeneron Pharmaceuticals, Inc is a biopharmaceutical company that discovers, invents, develops, manufactures and commercializes medicines for the treatment of serious medical conditions. The Company commercializes medicines for eye diseases, high low-density lipoprotein (LDL) cholesterol, and an inflammatory condition and have product candidates in development in other areas, including rheumatoid arthritis, asthma, atopic dermatitis, pain, cancer, and infectious diseases.
Receive News & Ratings for Regeneron Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regeneron Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.